MarketWatch (press release) ... for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. and more »
Medscape France Numéro 1 et 2 des ventes de médicaments du premier trimestre 2013 aux Etats-Unis : l'antipsychotique, aripiprazole , et l'IPP, ésoméprazole, pour des montants proches de 1,5 milliard de dollars. Auteur : Mark Grue, Vincent Richeux. Imprimer; Facebook ...
MarketWatch (press release) ... for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. and more »
MarketWatch (press release) ... for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. and more »
Oye! Times However, only one of these drugs, i.e. aripiprazole or Abilify, has been permitted for use in children, provided it is being used for the treatment of schizophrenia in teenagers 15 to 17. Additionally, reports highlighted that majority of the children ... and more »
Regina Leader-Post The drugs are being used for attention-deficit/hyperactivity disorder, “conduct” disorders, mood disorders, aggression and other behavioral problems. Only one — aripiprazole , or Abilify — has been officially approved for use in children, and only ...
Ottawa Citizen One 16-year-old boy who had been taking olanzapine for three months died from a diabetic coma. He was also taking two different anticonvulsant drugs at the time. Panagiotopoulos has seen several children who developed diabetic ketoacidosis — a ... and more »
MarketWatch (press release) ... for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. and more »
MarketWatch (press release) ... for New Therapies for TRD? also finds that surveyed pharmacy directors are more receptive to a therapy offering improvements in depressive symptoms over aripiprazole compared with a therapy offering improvements in weight gain or sexual dysfunction. and more »
Medscape Depression and pain agent duloxetine (Cymbalta, Eli Lilly), which faces end-of-year patent loss, came in third, topping rosuvastatin (Crestor, AstraZeneca). Both had first quarter sales of almost $1.3 billion. Asthma and COPD inhaler salmeterol ...
